Insignis Therapeutics
Insignis Therapeutics Inc.
Insignis Therapeutics is developing needle-free epinephrine delivery for the treatment of life-threatening allergic emergencies.
insignisrx.com · North Haven, CT
Funding event
The round itself, as filedInferred stageSeed
Sold of offered$6.0M of $8.5M
Filed2026-08-05
Days since filing60
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-06-11
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Mingbao ZhangExecutive Officer · Director
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged70.6% sold3.7 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-240
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
No open roles foundWe read careers pages daily.
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.